CO4700527A1 - Nuevos peptidos, su preparacion y su uso - Google Patents

Nuevos peptidos, su preparacion y su uso

Info

Publication number
CO4700527A1
CO4700527A1 CO96029751A CO96029751A CO4700527A1 CO 4700527 A1 CO4700527 A1 CO 4700527A1 CO 96029751 A CO96029751 A CO 96029751A CO 96029751 A CO96029751 A CO 96029751A CO 4700527 A1 CO4700527 A1 CO 4700527A1
Authority
CO
Colombia
Prior art keywords
residue
tert
norleucil
valyl
methyl
Prior art date
Application number
CO96029751A
Other languages
English (en)
Inventor
Andreas Haupt
Franz Emling
Cynthia A Romerdahl
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of CO4700527A1 publication Critical patent/CO4700527A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Péptidos novedosos de la fórmula IR1 R2 N-CHX-CO-A-B-D-E-(F)t-K I en donde R1 es metilo, etilo o isopropilo; R2 es hidrógeno, metilo o etileno; R1 -N-R2 juntos pueden ser un anillo de pirrolidina; A es un residuo de valil, isoleucil, leucil, 2-tert-butilglicil, 2-etilglicil-norleucil o norvalil; B es un residuo de N-metil-valil, -leucil,-isoleucil, norvalil, norleucil, 2-tert-butilglicil, -3-tert-butilalamil, o 2-etilglicil; D es un residuo 3,4-de hidroprolil, 4-fluoroprolil, 4,4-difluoroprolil, azetidina-2-carbonil, 3-metilprolil, 4-metilprolil, o 5-metilpropil; E es un residuo propil, homopropil,hidroxipropil o tiazolidina-4-carbonil;F es un residuo de valil, 2-tert-butilglicil- isoleucil, leucil, 2-ciclohexilglicil, norleucil, norvalil, neopentilglicil, alanil, ß-alanil o aminoisobutiroil;X es alkilo (preferiblemente C2-5 ), ciclopropil, o ciclopentilo; t es 0 o 1; y K es alkoxi (preferiblemente C1-4 ), benxiloxi o una traza amino substituida o no substituida; y las sales de los mismos con ácido tolerados fisiológicamente.
CO96029751A 1995-06-07 1996-06-07 Nuevos peptidos, su preparacion y su uso CO4700527A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides

Publications (1)

Publication Number Publication Date
CO4700527A1 true CO4700527A1 (es) 1998-12-29

Family

ID=23875567

Family Applications (2)

Application Number Title Priority Date Filing Date
CO96029751A CO4700527A1 (es) 1995-06-07 1996-06-07 Nuevos peptidos, su preparacion y su uso
CO96029749A CO4700526A1 (es) 1995-06-07 1996-06-07 Compuestos novedosos, la preparacion y el uso de estos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CO96029749A CO4700526A1 (es) 1995-06-07 1996-06-07 Compuestos novedosos, la preparacion y el uso de estos

Country Status (33)

Country Link
US (1) US5831002A (es)
EP (2) EP0871656B1 (es)
JP (2) JP4221062B2 (es)
KR (2) KR100437985B1 (es)
CN (2) CN1182154C (es)
AR (2) AR003427A1 (es)
AT (2) ATE224910T1 (es)
AU (2) AU725170B2 (es)
BG (2) BG102125A (es)
BR (2) BR9609423A (es)
CA (2) CA2219818C (es)
CO (2) CO4700527A1 (es)
CZ (2) CZ293682B6 (es)
DE (2) DE69623992T2 (es)
DK (2) DK0832104T3 (es)
ES (2) ES2186783T3 (es)
HR (2) HRP960257A2 (es)
HU (2) HU228071B1 (es)
IL (2) IL122215A (es)
MX (2) MX9709147A (es)
MY (2) MY119042A (es)
NO (2) NO318384B1 (es)
NZ (2) NZ310444A (es)
PL (2) PL185762B1 (es)
PT (2) PT871656E (es)
RO (2) RO118953B1 (es)
SI (2) SI0832104T1 (es)
SK (1) SK282466B6 (es)
TR (2) TR199701545T1 (es)
TW (2) TW508357B (es)
UA (2) UA46776C2 (es)
WO (2) WO1996040751A1 (es)
ZA (2) ZA964710B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6395897B1 (en) 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7018642B2 (en) 2001-04-27 2006-03-28 The Procter & Gamble Company Compounds, compositions, and methods for controlling biofilms
AU2002359792A1 (en) * 2001-12-18 2003-06-30 Proteologics, Inc. Methods and compositions for the inhibition of viral release
WO2003072754A2 (en) * 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
EP1924245A2 (en) * 2005-08-19 2008-05-28 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
EP1973928A2 (en) * 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
US8163792B2 (en) 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
CN101674835B (zh) * 2007-04-12 2013-12-11 台湾神隆股份有限公司 制备加兰他敏的方法
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EA201391756A1 (ru) * 2011-05-27 2014-05-30 Амбркс, Инк. Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
DK0934950T3 (da) * 1991-08-09 2002-07-29 Teikoku Hormone Mfg Co Ltd Tetrapeptidderivat
CZ292612B6 (cs) * 1992-05-20 2003-11-12 Abbott Gmbh & Co. Kg Peptid s protirakovinnou aktivitou, jeho použití a farmaceutický prostředek s obsahem takového peptidu
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters

Also Published As

Publication number Publication date
HUP9801910A3 (en) 1999-06-28
ATE224910T1 (de) 2002-10-15
IL122215A (en) 2001-08-26
DK0871656T3 (da) 2003-01-27
AU725164B2 (en) 2000-10-05
SK165397A3 (en) 1998-10-07
DE69623472T2 (de) 2003-08-21
NO975710D0 (no) 1997-12-05
NO975710L (no) 1998-02-02
MY124487A (en) 2006-06-30
US5831002A (en) 1998-11-03
PT871656E (pt) 2002-12-31
CA2219819A1 (en) 1996-12-19
HU228071B1 (hu) 2012-09-28
UA46775C2 (uk) 2002-06-17
CZ376397A3 (cs) 1998-06-17
PL185763B1 (pl) 2003-07-31
EP0871656B1 (en) 2002-09-25
ES2188759T3 (es) 2003-07-01
CN1182154C (zh) 2004-12-29
JPH11504652A (ja) 1999-04-27
CN1187198A (zh) 1998-07-08
RO118953B1 (ro) 2004-01-30
UA46776C2 (uk) 2002-06-17
DK0832104T3 (da) 2003-01-06
HU228073B1 (hu) 2012-09-28
KR19990022582A (ko) 1999-03-25
PL185762B1 (pl) 2003-07-31
PL323723A1 (en) 1998-04-14
TR199701545T1 (xx) 1998-04-21
DE69623992D1 (de) 2002-10-31
TR199701544T1 (xx) 1998-03-21
IL122216A0 (en) 1998-04-05
CA2219818C (en) 2008-05-20
NZ310443A (en) 1999-10-28
SI0871656T1 (en) 2003-08-31
ZA964710B (en) 1997-12-08
CN1187199A (zh) 1998-07-08
BR9609423A (pt) 1999-06-29
IL122216A (en) 2002-02-10
IL122215A0 (en) 1998-04-05
MX9709146A (es) 1998-03-31
BG102125A (en) 1998-09-30
DE69623472D1 (de) 2002-10-10
NO317670B1 (no) 2004-11-29
EP0832104B1 (en) 2002-09-04
CZ376597A3 (cs) 1998-06-17
WO1996040751A1 (en) 1996-12-19
WO1996040752A1 (en) 1996-12-19
ZA964711B (en) 1997-12-08
AR003136A1 (es) 1998-07-08
NO975711D0 (no) 1997-12-05
NO975711L (no) 1998-01-30
HUP9801817A3 (en) 1999-06-28
DE69623992T2 (de) 2003-05-22
TW508357B (en) 2002-11-01
AR003427A1 (es) 1998-08-05
NO318384B1 (no) 2005-03-14
HUP9801817A2 (hu) 1998-11-30
BR9609424A (pt) 2000-03-28
CO4700526A1 (es) 1998-12-29
NZ310444A (en) 1999-11-29
JP3957751B2 (ja) 2007-08-15
PL323726A1 (en) 1998-04-14
SI0832104T1 (en) 2003-08-31
AU725170B2 (en) 2000-10-05
CZ293682B6 (cs) 2004-07-14
KR100437986B1 (ko) 2004-09-18
MY119042A (en) 2005-03-31
PT832104E (pt) 2002-12-31
KR19990022583A (ko) 1999-03-25
HRP960257A2 (en) 1998-02-28
CN1182153C (zh) 2004-12-29
HRP960277A2 (en) 1997-10-31
CA2219818A1 (en) 1996-12-19
TW424096B (en) 2001-03-01
EP0832104A1 (en) 1998-04-01
ES2186783T3 (es) 2003-05-16
MX9709147A (es) 1998-03-31
EP0871656A1 (en) 1998-10-21
JPH11504653A (ja) 1999-04-27
KR100437985B1 (ko) 2004-09-18
AU6124296A (en) 1996-12-30
ATE223431T1 (de) 2002-09-15
JP4221062B2 (ja) 2009-02-12
HUP9801910A2 (hu) 1999-01-28
CZ293683B6 (cs) 2004-07-14
AU6124196A (en) 1996-12-30
CA2219819C (en) 2008-05-20
BG102152A (en) 1998-09-30
RO119783B1 (ro) 2005-03-30
SK282466B6 (sk) 2002-02-05

Similar Documents

Publication Publication Date Title
CO4700527A1 (es) Nuevos peptidos, su preparacion y su uso
TW334418B (en) Stilbene derivatives and pharmaceutical compositions
AR001440A1 (es) Nuevos taxoides, su preparación y composiciones farmacéuticas que los contienen.
BR9806296A (pt) Derivados de ácido sulfìnico e sua preparação e uso
AR038429A2 (es) Compuestos 15-alquil-16-hidroxilo de marcfortina
ES2183001T3 (es) Nuevo preparado medicamentoso estable para la produccion de aerosoles exentos de gas propulsor.
ES2195355T3 (es) Formulado farmaceutico que contiene voriconazol.
HUP0100043A2 (hu) Savérzékeny hatóanyagot tartalmazó új gyógyszerforma
IL145602A0 (en) Pharmaceutical compounds
ES2107284T3 (es) Nuevas n-piridil-carboxamidas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
MX9306988A (es) Antagonistas de bradicinina y composicion farmaceutica que los comprende.
ES2051754T3 (es) Uso de derivados cetonicos en el tratamiento de la depresion.
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
CO4940448A1 (es) Modificacion a cristal de una sustancia de medicamento
GB0227655D0 (en) Use
DK0736029T3 (da) Antikonvulsive pseudofructopyranosesulfamater
IT1243193B (it) Composizioni farmaceutiche orali a base di melatonina
NO970473D0 (no) N-substituerte 3-azabicyklo (3.2.0)heptanderivater egnet som neuroleptika
DK0452204T3 (da) Hidtil ukendte 3-aminochromanderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
HUP0000882A2 (hu) NMDA (N-metil-D-aszpartát) antagonista hatású indolszármazékok, valamint a vegyületeket tartalmazó gyógyszerkészítmények
ES2175181T3 (es) Analogos hexaciclicos de camptotecina y su procedimiento de preparacion.
ES2028871T3 (es) Un procedimiento para la preparacion de un glicosido de antraciclina. .
ES2086195T3 (es) Nuevos derivados pseudopeptidicos de actividad antagonista de la bradiquinina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2062066T3 (es) Derivados de la piperacina y su procedimiento de preparacion.
SG58291G (en) Anticonvulsant agents